


Efforts to visualize the pharmaceutical distribution process

When distributing prescription pharmaceuticals, we need to comply with GDP guidelines¹ on rigorous quality control. The MEDIPAL Group has partnered with a company that owns technologies for advanced temperature and vibration monitoring and jointly developed a cloud-based system that seamlessly monitors temperature and other data relevant for pharmaceutical quality control.



PoE-capable G-TAG² TempView (model number GT101-T)



¹ Good Distribution Practice: GDP guidelines set out appropriate procedures for ensuring the proper management of distribution (purchase, storage, and supply), maintaining the integrity of pharmaceuticals, and preventing the entry of counterfeit drugs into regular distribution channels.

² Operated by Power-over-Ethernet (PoE) supply and equipped with back-up battery and back-up memory functions to maintain data acquisition even during power outages, ensuring ongoing temperature measurement and data logging. PoE is a technology that allows electrical power to be transmitted alongside data over internet cables (LAN cables).

VOICE

Contributing to pharmaceutical quality control



Yoshiaki Tomofuji
GDP Manager
Logistics Division
MEDICEO CORPORATION

Traceability across all distribution channels is important for pharmaceutical quality control. In the future, we envision achieving end-to-end temperature traceability and visibility in the pharmaceutical supply chain, starting from storage at pharmaceutical companies, passing through wholesalers, and extending to medical facilities and even patients' homes, by combining the smart-sensing S3 PLATFORM product developed by our partner SHINYEI KAISHA and management systems from other companies. Moreover, the newly developed temperature logger has back-up functionality, ensuring ongoing temperature measurement and data logging.


We expect to apply these functions in support of pharmaceutical quality control so that there is no loss of traceability across all distribution channels.

MEDISKET CORPORATION

Building the largest healthcare distribution platform in Japan to support “Pharmaceuticals, Health, and Beauty”

In April 2022, MEDISKET CORPORATION was established as a joint venture between MEDIPAL HOLDINGS CORPORATION and H.U. Group Holdings, Inc. By combining logistics for the prescription pharmaceutical wholesaling business and the contract clinical testing business, MEDISKET optimizes the supply of pharmaceuticals, clinical testing materials, and other items, as well as the collection of test specimens from clinical laboratories, clinical trials, and research. It also provides high-quality logistics services that conform to GDP guidelines.

MEDISKET CORPORATION handles goods to which third parties have ownership rights, thereby promoting participation by various companies active in the healthcare field. In addition, it contributes to society by more quickly resolving global environmental issues such as the reduction of greenhouse gas emissions, as demanded by society. Aside from seeking greater efficiency by combining distribution functions, MEDISKET also creates new profit opportunities through logistics outsourcing services for external companies. We will promote MEDISKET as an initiative that will lead to building sustainable logistics, which is one of the growth strategies of the 2027 MEDIPAL Medium-Term Vision: “Change the Oroshi Forever: Constant Innovation.”



Operations started in December 2022, completed the transfer of approximately 40 sites in the pharmaceutical wholesale business and contracted business of laboratory testing

Now licensed for general freight vehicle transportation business, investigating possible commercialization of sharing logistics*



Aims to complete preparations for sharing logistics infrastructure by FY2024

* Combined transportation and delivery of pharmaceuticals and laboratory test samples